{"id":110885,"date":"2026-05-18T13:02:40","date_gmt":"2026-05-18T11:02:40","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/research-led-by-ibmb-csic-develops-a-recombinant-molecule-to-treat-celiac-disease\/"},"modified":"2026-05-18T15:52:08","modified_gmt":"2026-05-18T13:52:08","slug":"research-led-by-ibmb-csic-develops-a-recombinant-molecule-to-treat-celiac-disease","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/research-led-by-ibmb-csic-develops-a-recombinant-molecule-to-treat-celiac-disease\/","title":{"rendered":"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease"},"content":{"rendered":"<p><strong>Research led by the Institute of Molecular Biology of Barcelona of the Spanish National Council for Scientific Research (<a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/institut-de-biologia-molecular-de-barcelona-ibmb-csic\/\" target=\"_blank\" rel=\"noopener\">IBMB-CSIC<\/a>), located in the Barcelona Science Park (PCB-UB), the Institute for Research in Nutrition and Food Safety (INSA) and the Faculty of Pharmacy and Food Sciences of the University of Barcelona (<a href=\"https:\/\/web.ub.edu\/en\/\" target=\"_blank\" rel=\"noopener\">UB<\/a>) has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.<\/strong><\/p>\n<p>There is currently a complete lack of therapeutic alternatives beyond a gluten-free diet, which is difficult to maintain in Western societies based on wheat consumption. The major breakthrough is that the molecule is effective at very low concentrations and under pH 2 conditions\u2014those of the stomach\u2014something that none of the molecules currently available have been able to achieve to a relevant extent. Although these are marketed as nutritional supplements, they do not provide an effective alternative to gluten-free diets.<\/p>\n<p>The study has been published in the journal EMBO Molecular Medicine and is led by researchers <strong>F. Xavier Gomis-R\u00fcth<\/strong>, from IBMB-CSIC, and <strong>Francisco J. P\u00e9rez Cano<\/strong>, from INSA-UB. Its first authors are <strong>Marina Girbal-Gonz\u00e1lez<\/strong> and <strong>Arturo Rodr\u00edguez Banqueri<\/strong>, from INSA-UB and IBMB-CSIC, respectively. Teams from the Institute of Food Science Research (CSIC-UAM), the University of Salzburg (Austria), and the Technical University of Munich (Germany) also participated.<\/p>\n<p><strong>Counteract the \u201ctrigger\u201d of coeliac disease<\/strong><\/p>\n<p>The trigger of coeliac disease is prolamins, a group of proteins found in most common cereals in our diet, such as gliadin in wheat gluten. When these proteins are digested in the stomach, they are broken down into smaller fragments (peptides). Some of these can be toxic, such as gluten immunogenic peptides (GIPs), which are able to resist gastric acids and reach the small intestine. Among them, the \u201c33-mer\u201d stands out\u2014a fragment of \u03b1-gliadin from wheat gluten that is highly immunogenic.<\/p>\n<p>This poses a problem for people with coeliac disease, because once they reach the small intestine, the 33-mer and other GIPs bind very readily to a receptor of the immune system (the human leukocyte antigen, or HLA), thereby triggering the inflammatory autoimmune response that leads to the characteristic manifestations of the disease.<\/p>\n<p>Four years ago, the <a href=\"https:\/\/ibmb.csic.es\/en\/department-of-structural-and-molecular-biology\/proteolysis-lab\/\" target=\"_blank\" rel=\"noopener\">Proteolysis Group at IBMB-CSIC<\/a>, led by <strong>F. Xavier Gomis-R\u00fcth<\/strong>, reported in a <em>Nature Communications<\/em> article that neprosin\u2014a molecule naturally found in the digestive fluid of the carnivorous plant <em>Nepenthes ventrata<\/em>\u2014is able to cleave GIPs. In collaboration with the Autoimmunity, Immunonutrition and Tolerance group at the Faculty of Pharmacy and Food Sciences of the University of Barcelona, led by <strong>Francisco Jos\u00e9 P\u00e9rez Cano<\/strong>, they showed that neprosin can degrade the 33-mer peptide and other GIPs before they reach the intestine, thereby potentially preventing this inflammatory autoimmune response.<\/p>\n<h3><strong>Designed through molecular engineering<\/strong><\/h3>\n<p>In the new study, the team designed and tested a variant derived from neprosin. Named celiacase, this new molecule shows peak activity at the stomach\u2019s gastric pH and, in synergy with pepsin from our digestive system, is able to break down cereal GIPs and wheat gliadin before they pass into the duodenum.<\/p>\n<p>\u201cThere are other proteases, generally referred to as glutenases, that degrade gluten, but they are not fully active under pH 2 conditions\u2014the stomach\u2019s pH\u2014rather at pH 7, that of the duodenum, when the predigested food has already left the stomach,\u201d explains <strong>Gomis-R\u00fcth<\/strong>. \u201cThis makes it necessary to increase the doses to levels that make them unviable for therapeutic use&#8221;.<\/p>\n<p>The team tested the molecule in vivo using a mouse model developed by the University of Chicago, currently the one that best reproduces coeliac disease. The results show that celiacase is effective at very low doses and is able to attenuate the manifestations of the disease in mice receiving gluten, even in high amounts. \u201cIntestinal atrophy, inflammation, the antibody response and dysbiosis\u2014that is, alterations in the composition of the microbiota\u2014were reduced,\u201d says <strong>P\u00e9rez Cano<\/strong>. \u201cIn addition, immunoregulatory markers were restored to normal levels, as were microbial metabolic pathways.\u201d<\/p>\n<p>The results show that celiacase, a molecule stable under stomach acid conditions, could serve as an adjunct therapeutic alternative to a gluten-free diet.<\/p>\n<p>Un altre avantatge de la celiacasa \u00e9s que a partir del duod\u00e8 ja no \u00e9s activa. \u201cQuan ha fet la seva funci\u00f3, ja no interessa que segueixi activa, perqu\u00e8 no interfereixi amb cap altra prote\u00efna de l\u2019organisme\u201d, afegeix <strong>Gomis-Ruth<\/strong>.<\/p>\n<p>The molecule and its potential applications have been protected by a patent, and the team is taking the first steps to create a spin-off and move the development towards more advanced stages, for which they are interested in securing funding.<\/p>\n<p><strong>\u00bb Article of reference: <\/strong>Marina Girbal-Gonz\u00e1lez, Arturo Rodr\u00edguez-Banqueri, Hadeel Swaid, Soraia R. Mendes, Laura Garz\u00f3n-Flores, Juan Sebasti\u00e1n Ram\u00edrez-Larrota, Carolina Cueva, M. Victoria Moreno-Arribas, Christof Regl, Christian G. Huber, Katharina A. Scherf, Mar\u00eda Jos\u00e9 Rodr\u00edguez-Lagunas, \u00c0ngels Franch-Masferrer, Ulrich Eckhard, Francisco J. P\u00e9rez-Cano and F. Xavier Gomis-R\u00fcth. Targeted enzymatic therapy for coeliac disease. EMBO Molecular Medicine. DOI: <a href=\"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00430-8\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00430-8<\/a>.<\/p>\n<p><strong>\u00bb Link to the news: <\/strong><a href=\"https:\/\/delegacion.catalunya.csic.es\/una-molecula-disenada-en-el-laboratorio-e-inspirada-en-la-naturaleza-prometedora-alternativa-para-la-celiaquia\/\" target=\"_blank\" rel=\"noopener\">CSIC Catalunya website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Research led by the Institute of Molecular Biology of Barcelona of the Spanish National Council for Scientific Research (IBMB-CSIC), located in the Barcelona Science Park (PCB-UB), the Institute for Research&#8230;<\/p>\n","protected":false},"author":14,"featured_media":110879,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[335],"class_list":["post-110885","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science","tag-ibmb-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"Research led by IBMB-CSIC has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Research led by IBMB-CSIC has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T11:02:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-18T13:52:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease\",\"datePublished\":\"2026-05-18T11:02:40+00:00\",\"dateModified\":\"2026-05-18T13:52:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/\"},\"wordCount\":858,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp\",\"keywords\":[\"IBMB\"],\"articleSection\":[\"SCIENCE\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/\",\"name\":\"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp\",\"datePublished\":\"2026-05-18T11:02:40+00:00\",\"dateModified\":\"2026-05-18T13:52:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"Research led by IBMB-CSIC has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease - Parc Cient\u00edfic de Barcelona","description":"Research led by IBMB-CSIC has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/","og_locale":"en_US","og_type":"article","og_title":"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease - Parc Cient\u00edfic de Barcelona","og_description":"Research led by IBMB-CSIC has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.","og_url":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-05-18T11:02:40+00:00","article_modified_time":"2026-05-18T13:52:08+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp","type":"image\/webp"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease","datePublished":"2026-05-18T11:02:40+00:00","dateModified":"2026-05-18T13:52:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/"},"wordCount":858,"image":{"@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp","keywords":["IBMB"],"articleSection":["SCIENCE"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/","url":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/","name":"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp","datePublished":"2026-05-18T11:02:40+00:00","dateModified":"2026-05-18T13:52:08+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"Research led by IBMB-CSIC has successfully designed and tested a gluten-degrading molecule that could be a promising ally for the management of celiac disease.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/5d8f122d-4fcf-4079-af9e-b4515972e984_source-aspect-ratio_default_0_x600y225-1.webp","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/una-recerca-liderada-per-libmb-csic-desenvolupa-una-molecula-recombinant-per-a-tractar-la-celiaquia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Research led by IBMB-CSIC develops a recombinant molecule to treat celiac disease"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=110885"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110885\/revisions"}],"predecessor-version":[{"id":110888,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110885\/revisions\/110888"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/110879"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=110885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=110885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=110885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}